DreaMed deploys its AI Diabetes solution with the University of Florida

  (photo credit: INGIMAGE)
(photo credit: INGIMAGE)

This week, DreaMed Diabetes announced it would expand its strategic commercial relationship with the University of Florida’s Pediatric Endocrinology Clinic – a substantial milestone for the promising Israeli start-up.

Today, there is no known cure for diabetes. As the disease continues to affect tens of millions in the United States and other developed countries around the world, few institutions have been successful in producing solutions that aid diabetes patients. While regular exercise and a nutritious diet are the first steps in regulating a diabetes-healthy lifestyle, especially in regard to managing blood sugar levels, one company has designed a promising and innovative medical device that utilizes artificial intelligence and specialized in endocrinological care. 

Founded in 2014, Israeli biotech start-up DreaMed Diabetes has emerged as one of the world’s leading medical device enterprises and is promptly aiming to implement its user-friendly Advisor Pro healthcare technology in strategic medical centers. After ten years of development and experimentation, the Advisor Pro Decision-Support System is considered one of the most cutting-edge machines on the market. DreaMed’s signature device uses artificial intelligence (AI) algorithms to evaluate diabetes patients just as an endocrinologist would, including accumulating information like collating, analyzing bloodwork, and storing every individual patient’s data so that treatments are optimized to their specific medical needs. 

In today’s medical climate, proper diabetes management requires an exceptionally unique personalized treatment plan. This is where DreaMed seeks to play an innovative and significant role for hospitals, clinics, and medical institutions in major population centers. Since each individual patient maintains a unique diabetic profile, the Advisor Pro’s ability to conduct person-specific insulin monitoring is vital and incorporates data preservation stored from a patient’s CGM, SMGB, and insulin pump. The patient’s data is then organized via MD Logic-based algorithm, therefore simplifying the comprehensive therapeutic process, an urgent demand of endocrinologists who are caring for thousands of patients on a daily basis. 

This week, the company announced that it intends to expand its collaboration with the University of Florida’s Pediatric Endocrinology Clinic, located in Jacksonville, FL. In the coming months, the University of Florida will be using the Advisor Pro Decision-Support System for people with Type 2 and Type 1 diabetes, enhancing the center’s ability and efficiency for its medical staff as well as patients. This decision came following a successful pilot launch, where in late 2020 and throughout 2021 the University of Florida began to commence a trial program for the AI-backed DreaMed Advisor and later its upgraded Advisor Pro.

For DreaMed Diabetes, its success in achieving its initial implementation with premier diabetes inclusive medical centers succeeds its prestigious acknowledgment by Nature Medicine, one of the world’s most historic scientific journals. In September 2020, the magazine published an extensive international research study that featured the University of Florida’s Pediatric Endocrinology Clinic as a participating institute. The six-month study, which comprised of several medical centers over several nations, resulted in a conclusion that when using the DreaMed Advisor system there was an equal improvement in clinical outcomes compared with in-person physician recommendations. 

According to Dr. Michael Haller of the Pediatric Endocrinology Clinic at the University of Florida, “digital medicine applications can vastly improve the access of patients to healthcare. During the COVID-19 pandemic, we have seen how remote medicine can perform a productive role in the future of healthcare. Now with DreaMed’s Advisor system, hospitals and clinics like ours will possess the capability to deploy remote care solutions and deliver better care to diabetes and other suffering patients.” Over the past few years, DreaMed has forged several critical partnerships with prominent American medical institutions, including Yale-New Haven Health and Texas Children's Hospital – both serving tens of thousands of diabetes patients annually. 

Earlier this month, DreaMed received clearance from the United States Food and Drug Administration (FDA) for its Diabetes AI-based machine, which currently covers Type 2 diabetes as well as Type 1. This achievement is considered a notable milestone for the company and enables it to finalize its commercialization process. According to Founder and CEO Eran Atlas, "This was our fourth FDA clearance for our Type 1 & Type 2 solutions. Our most recent commercialization authorization has enabled the Advisor Pro system to monitor a broader range of patients and opened the door to increased relationships with premier children's hospitals in order to improve their diabetes healthcare management for years to come.”

While diabetes continues to be one of the leading causes of medical complications and death in the United States, Europe, and beyond, DreaMed Diabetes aims to represent a disruptive force in the endocrinology market. Since the company’s recent FDA approvals, DreaMed has been further implementing its Advisor Pro medical device into various hospitals and treatment centers in strategic locations – this week announcing its expansion with the University of Florida Pediatric Endocrinology Clinic. As the enterprise sets out to additionally expand its reach, investors should presently be paying attention; when DreaMed eventually goes public, these initial triumphs will be crucial in determining its long-term evaluation. 

This article was written in cooperation with Sudip Mazumdar